September 21 news. Recently, Medtronic, a global giant medical device manufacturer, and Mazor, a specialist surgical robot manufacturer, announced a strategic cooperation agreement of US $ 1.64 billion. Less than an hour after the announcement, Mazor shares rose 7.5% and Medtronic shares fell less than 0.1%.
Globally, Medtronic will market Mazor spinal surgery "rejuvenation robots".
It is reported that the use of Mazor "revival robot" greatly reduces the passive exposure to radiation due to filming during surgery. Compared with conventional spinal surgery, the use of Mazor "revival robot" assisted surgery reduced the radiation dose received by patients and doctors by 56%. More importantly, the patient's recovery process is significantly shortened, and fewer adverse complications (spinal cord plexus injury and scar crust) are observed.
Mazor's sales in the first quarter of this year reached $ 64 million, a 42% increase from last year. Based on this, it is estimated that the sustainable growth rate of sales profits this year will be about 41%.
At present, Mazor's "revival robot" has sold 100 units worldwide, and the clinical application effect is very good. The Mazor robot can assist surgeons to formulate surgical plans and procedures in advance. Once the surgical site of the patient's spine is fixed, the robot can automatically complete the surgical steps without the need for doctors to participate.